<< CSR 1975-2008 Home

The navigation below allows you to jump to any table or figure within the SEER Cancer Statistics Review.

  1. First select the CSR Section, then a Table/Figure from that section.
  2. Use the Submit button to view the table or figure. You will have options to download a printer-friendly version (PDF) or the data table (CSV) as well.

To learn more about the Cancer Statistics Review and the statistics presented in this report, refer to the About the CSR (PDF, 523 KB) and Technical Notes (PDF, 687 KB) pages.


Download and Print: Download Printer-friendly PDF Download data

Table 1.21

U.S. Prevalence Counts, Invasive Cancers Only, January 1, 2008a Using Different Tumor Inclusion Criteriab
Site Sex 5-Year Limited Duration Prevalence 33-year Limited Duration Prevalence
1st Invasive
Tumor Everc		 1st Per Site in
Previous 33 Yearsd		 1st Per Site in
Previous 5 Yearse		 1st Invasive
Tumor Everc		 1st Per Site in
Previous 33 Yearsd
All Sites Both Sexes 4,249,706 4,331,842 4,734,286 11,688,972 11,892,768
Male 2,188,126 2,219,768 2,413,895 5,506,074 5,570,768
Female 2,061,580 2,112,074 2,320,391 6,182,898 6,322,000
Oral Cavity & Pharynx Both Sexes 94,344 107,847 111,563 245,098 269,441
Male 65,141 73,776 76,117 159,807 174,074
Female 29,203 34,071 35,446 85,291 95,367
Esophagus Both Sexes 19,829 23,939 23,951 30,597 35,817
Male 15,229 18,405 18,417 23,362 27,236
Female 4,600 5,534 5,534 7,235 8,581
Stomach Both Sexes 33,089 39,300 39,521 65,498 74,863
Male 19,927 23,973 24,073 37,436 43,123
Female 13,162 15,327 15,448 28,062 31,740
Colon & Rectum Both Sexes 407,014 469,977 478,669 1,098,089 1,223,141
Male 205,716 237,703 241,917 540,332 598,652
Female 201,298 232,274 236,752 557,757 624,489
Liver & Intrahepatic Bile Duct Both Sexes 23,568 26,629 26,633 31,341 34,942
Male 17,221 19,339 19,343 21,890 24,282
Female 6,347 7,290 7,290 9,451 10,660
Pancreas Both Sexes 26,137 31,728 31,739 34,955 41,506
Male 12,950 15,750 15,761 16,972 20,161
Female 13,187 15,978 15,978 17,983 21,345
Larynx Both Sexes 30,287 36,587 36,906 87,991 98,455
Male 24,152 29,051 29,312 70,449 78,408
Female 6,135 7,536 7,594 17,542 20,047
Lung & Bronchus Both Sexes 220,060 276,893 283,557 371,171 450,808
Male 103,405 130,714 133,454 171,338 207,978
Female 116,655 146,179 150,103 199,833 242,830
Melanoma of the Skin Both Sexes 252,206 283,584 294,513 796,296 855,750
Male 133,991 153,602 160,698 394,107 428,125
Female 118,215 129,982 133,815 402,189 427,625
Breast Female 805,515 868,236 918,683 2,606,497 2,763,127
Cervix Female 38,294 40,160 40,257 200,357 206,078
Corpus & Uterus, NOS Female 154,529 174,300 174,371 541,737 589,947
Ovaryf Female 54,970 63,837 63,889 161,711 181,687
Prostate Male 970,359 1,048,069 1,048,105 2,396,871 2,555,936
Testis Male 40,125 40,828 41,397 187,670 190,120
Urinary Bladder Both Sexes 194,097 239,746 244,623 531,166 614,655
Male 146,585 181,724 185,560 395,025 456,695
Female 47,512 58,022 59,063 136,141 157,960
Kidney & Renal Pelvis Both Sexes 128,486 155,791 157,332 290,688 337,899
Male 77,495 95,049 96,135 171,540 201,021
Female 50,991 60,742 61,197 119,148 136,878
Brain & Nervous System Both Sexes 40,898 43,394 43,831 116,955 120,623
Male 22,693 24,140 24,351 62,642 64,690
Female 18,205 19,254 19,480 54,313 55,933
Thyroid Both Sexes 139,961 153,689 154,081 425,181 450,805
Male 31,088 35,530 35,602 93,227 100,569
Female 108,873 118,159 118,479 331,954 350,236
Hodgkin Lymphoma Both Sexes 36,835 39,099 39,099 155,837 159,846
Male 19,688 20,808 20,808 80,709 82,717
Female 17,147 18,291 18,291 75,128 77,129
Non-Hodgkin Lymphoma Both Sexes 189,410 220,661 222,116 452,242 502,943
Male 98,768 116,412 117,193 234,240 260,923
Female 90,642 104,249 104,923 218,002 242,020
Myeloma Both Sexes 42,726 49,682 49,741 65,682 74,814
Male 23,046 27,105 27,164 36,054 41,454
Female 19,680 22,577 22,577 29,628 33,360
Leukemia Both Sexes 103,646 117,597 117,772 252,119 274,930
Male 59,538 68,094 68,189 142,621 155,942
Female 44,108 49,503 49,583 109,498 118,988
Acute Lymphocytic Leukemia Both Sexes 15,402 15,740 15,740 59,985 60,486
Male 8,796 8,940 8,940 33,127 33,297
Female 6,606 6,800 6,800 26,858 27,189
Childhood (Ages 0-19) Both Sexes 59,739 59,851 60,342 277,294 277,798
Male 31,980 32,036 32,261 142,787 143,010
Female 27,759 27,815 28,081 134,507 134,788
Kaposi Sarcoma Both Sexes 6,661 7,109 7,109 22,566 23,720
Male 6,221 6,561 6,561 21,226 22,190
Female 440 548 548 1,340 1,530
Mesothelioma Both Sexes 3,148 3,988 3,988 4,609 5,619
Male 2,120 2,735 2,735 2,681 3,419
Female 1,028 1,253 1,253 1,928 2,200

Footnotes:

a U.S. 2008 cancer prevalence counts are based on 2008 cancer prevalence proportions from the SEER 9 registries and 1/1/2008 U.S. population estimates based on the average of 2007 and 2008 population estimates from the U.S. Bureau of the Census.

b Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion which are listed in footnotes (c) to (e).

c First invasive tumor ever. Referred to as method (c) in Example below.

d First invasive tumor for each cancer site diagnosed during the previous 33 years (1975-2007). All sites is treated as a separate cancer "site". Referred to as method (d) in Example below.

e First invasive tumor for each cancer site diagnosed during the previous 5 years (2003-2007). All sites is treated as a separate cancer "site". Referred to as method (e) in Example below.

Example: Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 2003; Melanoma in 2004.
In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 33-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred more than 5 years prior to 1/1/2008.
In method (d) the 1981 melanoma is counted for the melanoma and all sites 33-year limited duration prevalence. The 2003 breast cancer is counted for the breast 5-year and 33-year limited duration prevalence.
In method (e) the 2003 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 2004 melanoma is counted for 5-year limited duration prevalence for melanoma.

f Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

Page Navigation: << Previous Next >>

The information on this page is archived and provided for reference purposes only. Persons with disabilities having difficulty accessing information on this page may e-mail for assistance.